Skip to content
value.today

Merrimack Pharmaceuticals Inc.

🇺🇸 Cambridge, Massachusetts, USAPharmaceuticalsFounded 2010
Total raised
$77 M
1 round on record
Latest round
$77 M
Apr 2011
First round on record
Apr 2011
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Merrimack Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2011$77 MNo. 1$50 to $250 million

Merrimack Pharmaceuticals Inc.: Raise no. 1, Apr 2011

Investors in this round

61 investors had bought by the notice of Apr 13, 2011: 61 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$77 M of $77 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Robert J. Mulroy · Executive Officer, Director
  • William A. Sullivan · Executive Officer
  • Anthony A. Sinskey · Director
  • Gary A. Crocker · Director
  • Gordon A. Fehr · Director
  • James A. Dresser · Director
  • Michael A. Porter · Director
  • Robert A. Gay · Director
  • Sarah A. Nash · Director
  • Walter A. Lovenberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William A. Sullivan, Vice President of Finance. Newest notice filed Apr 13, 2011. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Merrimack Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2011).

    SEC Form D · Apr 2011

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2011

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Merrimack Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Merrimack Pharmaceuticals Inc.
NameRoleNamed in
Robert J. MulroyExecutive officerApr 2011
William A. SullivanExecutive officerApr 2011
Anthony A. SinskeyDirectorApr 2011
Gary A. CrockerDirectorApr 2011
Gordon A. FehrDirectorApr 2011
James A. DresserDirectorApr 2011
Michael A. PorterDirectorApr 2011
Robert A. GayDirectorApr 2011
Robert J. MulroyDirectorApr 2011
Sarah A. NashDirectorApr 2011
Walter A. LovenbergDirectorApr 2011